ES3005832T3 - Dual run cassette for the synthesis of 18f-labelled compounds - Google Patents
Dual run cassette for the synthesis of 18f-labelled compounds Download PDFInfo
- Publication number
- ES3005832T3 ES3005832T3 ES14796762T ES14796762T ES3005832T3 ES 3005832 T3 ES3005832 T3 ES 3005832T3 ES 14796762 T ES14796762 T ES 14796762T ES 14796762 T ES14796762 T ES 14796762T ES 3005832 T3 ES3005832 T3 ES 3005832T3
- Authority
- ES
- Spain
- Prior art keywords
- cassette
- spe
- reaction vessel
- column
- aliquot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 49
- 238000003786 synthesis reaction Methods 0.000 title claims description 40
- 230000015572 biosynthetic process Effects 0.000 title claims description 38
- 230000009977 dual effect Effects 0.000 title 1
- 239000000700 radioactive tracer Substances 0.000 claims abstract description 29
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 34
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 claims description 29
- 238000002600 positron emission tomography Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000004140 cleaning Methods 0.000 claims description 21
- 238000005349 anion exchange Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000010511 deprotection reaction Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- HIIJZYSUEJYLMX-JZRMKITLSA-N 1-fluoranyl-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound [18F]CC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-JZRMKITLSA-N 0.000 claims description 5
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- LPZSRGRDVVGMMX-FJBGPTLJSA-N (2s,3s,4s,5s)-2-(fluoranylmethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](C[18F])[C@@H](O)[C@H](O)[C@H]1N1C([N+]([O-])=O)=NC=C1 LPZSRGRDVVGMMX-FJBGPTLJSA-N 0.000 claims description 3
- LPZSRGRDVVGMMX-JWXFUTCRSA-N (2s,3s,4s,5s)-2-(fluoromethyl)-5-(2-nitroimidazol-1-yl)oxolane-3,4-diol Chemical compound O1[C@H](CF)[C@@H](O)[C@H](O)[C@H]1N1C([N+]([O-])=O)=NC=C1 LPZSRGRDVVGMMX-JWXFUTCRSA-N 0.000 claims description 3
- HNIHOFVDKWEICB-KWCOIAHCSA-N 1-(18F)fluoranylcyclobutane-1-carboxylic acid Chemical compound [18F]C1(CCC1)C(=O)O HNIHOFVDKWEICB-KWCOIAHCSA-N 0.000 claims description 3
- UXCAQJAQSWSNPQ-KXMUYVCJSA-N 1-[4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C([18F])C1 UXCAQJAQSWSNPQ-KXMUYVCJSA-N 0.000 claims description 3
- XUUGOSKUEDWDAS-COJKEBBMSA-N 2-(2-fluoranylethoxy)ethyl-trimethylazanium Chemical compound C[N+](C)(C)CCOCC[18F] XUUGOSKUEDWDAS-COJKEBBMSA-N 0.000 claims description 3
- IKWJWCZWJVPPIC-RVRFMXCPSA-N 2-[(4-fluoranyl-3-iodophenyl)methyl]guanidine Chemical compound NC(N)=NCC1=CC=C([18F])C(I)=C1 IKWJWCZWJVPPIC-RVRFMXCPSA-N 0.000 claims description 3
- SMYALUSCZJXWHG-VNRZBHCFSA-N 3-[2-[4-(4-fluoranylbenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1h-quinazolin-4-one Chemical compound C1=CC([18F])=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=S)=O)CC1 SMYALUSCZJXWHG-VNRZBHCFSA-N 0.000 claims description 3
- GHASVSINZRGABV-SFIIULIVSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound [18F]C1=CNC(=O)NC1=O GHASVSINZRGABV-SFIIULIVSA-N 0.000 claims description 3
- 102100030771 Ferrochelatase, mitochondrial Human genes 0.000 claims description 3
- 101000843611 Homo sapiens Ferrochelatase, mitochondrial Proteins 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- OFBIFZUFASYYRE-GKTGUEEDSA-N ethyl 8-fluoranyl-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate Chemical compound C1N(C)C(=O)C2=CC([18F])=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-GKTGUEEDSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- HIIJZYSUEJYLMX-UHFFFAOYSA-N 1-fluoro-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound FCC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-UHFFFAOYSA-N 0.000 claims 2
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- ZCXUVYAZINUVJD-GLCXRVCCSA-N [18F]fluorodeoxyglucose Chemical compound OC[C@H]1OC(O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-GLCXRVCCSA-N 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000001044 reversed-phase solid-phase extraction Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012351 deprotecting agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HWVGAQJJDGOCDG-YCSXTYHYSA-N (4S,5R,6R)-4,5-diacetyl-6-[(1S)-1-(18F)fluoranyl-1,2-dihydroxyethyl]-4,5,6-trihydroxyoctane-2,3,7-trione Chemical compound [18F][C@@]([C@]([C@@]([C@](C(=O)C(C)=O)(O)C(C)=O)(O)C(C)=O)(O)C(C)=O)(O)CO HWVGAQJJDGOCDG-YCSXTYHYSA-N 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 2
- UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 1-[(2r,4s,5r)-4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H]([18F])C1 UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 0.000 description 2
- NTEDWGYJNHZKQW-KWCOIAHCSA-N 1-amino-3-fluoranylcyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(N)CC([18F])C1 NTEDWGYJNHZKQW-KWCOIAHCSA-N 0.000 description 2
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical group [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 239000002739 cryptand Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 150000002222 fluorine compounds Chemical class 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010884 ion-beam technique Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229910003594 H2PtCl6.6H2O Inorganic materials 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 229920004738 ULTEM® Polymers 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00495—Means for heating or cooling the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00709—Type of synthesis
- B01J2219/00716—Heat activated synthesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00731—Saccharides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903486P | 2013-11-13 | 2013-11-13 | |
| PCT/EP2014/074330 WO2015071288A1 (en) | 2013-11-13 | 2014-11-12 | Dual run cassette for the synthesis of 18f-labelled compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3005832T3 true ES3005832T3 (en) | 2025-03-17 |
Family
ID=51897262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14796762T Active ES3005832T3 (en) | 2013-11-13 | 2014-11-12 | Dual run cassette for the synthesis of 18f-labelled compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10584078B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3068747B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6496726B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102335535B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104762666A (cg-RX-API-DMAC7.html) |
| BE (1) | BE1022357A9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2930479C (cg-RX-API-DMAC7.html) |
| DE (2) | DE202014010612U1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3068747T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3005832T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3068747T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20250050T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE069777T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL235650B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3068747T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3068747T (cg-RX-API-DMAC7.html) |
| RS (1) | RS66442B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015071288A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201420094D0 (en) * | 2014-11-12 | 2014-12-24 | Ge Healthcare Ltd | Flouride trapping arrangement |
| US10109385B2 (en) | 2009-09-23 | 2018-10-23 | Abt Molecular Imaging, Inc. | Dose synthesis card for use with automated biomarker production system |
| US10584078B2 (en) * | 2013-11-13 | 2020-03-10 | Ge Healthcare Limited | Dual run cassette for the synthesis of 18F-labelled compounds |
| GB201420093D0 (en) | 2014-11-12 | 2014-12-24 | Ge Healthcare Ltd | Pet tracer purification system |
| CN107530455A (zh) * | 2015-02-10 | 2018-01-02 | Abt分子成像公司 | 与自动化生物标记物生产系统联用的剂量合成卡 |
| GB201504287D0 (en) | 2015-03-13 | 2015-04-29 | Ge Healthcare Ltd | Piercing device |
| NL2014828B1 (en) | 2015-05-20 | 2017-01-31 | Out And Out Chemistry S P R L | Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method. |
| JP6913968B2 (ja) | 2017-06-19 | 2021-08-04 | フューチャーケム カンパニー リミテッドＦｕｔｕｒｅｃｈｅｍ Ｃｏ．，Ｌｔｄ． | 前立腺がんの診断のための１８ｆ標識化合物およびその使用 |
| WO2018236115A1 (ko) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
| WO2019058947A1 (ja) * | 2017-09-19 | 2019-03-28 | 株式会社村田製作所 | 濾過装置及び濾過方法 |
| CN111107920A (zh) | 2017-09-25 | 2020-05-05 | 株式会社村田制作所 | 过滤装置 |
| CN108126648A (zh) * | 2018-01-04 | 2018-06-08 | 江苏华益科技有限公司 | 一种放射性药物的自动传输装置及方法 |
| CN113413840A (zh) * | 2021-06-04 | 2021-09-21 | 四川玖谊源粒子科技有限公司 | 一种用于制备多核素放射性药物的合成系统 |
| BE1032491B1 (fr) | 2024-03-27 | 2025-10-27 | Trasis S A | Synthèse de traceurs à plusieurs passages sur cassette |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082980A (en) * | 1990-06-13 | 1992-01-21 | Case Western Reserve University | Process and apparatus for synthesizing oxygen-15 labelled butanol for positron emission tomography |
| US7413714B1 (en) | 2000-07-16 | 2008-08-19 | Ymc Co. Ltd. | Sequential reaction system |
| CN100374453C (zh) * | 2005-11-18 | 2008-03-12 | 南方医科大学南方医院 | 2－18f－2－脱氧－d－葡萄糖的合成工艺 |
| WO2007063940A1 (ja) * | 2005-12-02 | 2007-06-07 | Nihon Medi-Physics Co., Ltd. | 放射性フッ素標識化合物の製造方法 |
| JP4926546B2 (ja) | 2006-05-30 | 2012-05-09 | 住友重機械工業株式会社 | 放射性薬液合成装置の使用方法、及び放射性薬液合成装置 |
| KR20110106895A (ko) * | 2008-12-22 | 2011-09-29 | 바이엘 파마 악티엔게젤샤프트 | 교환 수지를 사용하여 방사성핵종-표지된 화합물을 합성하는 방법 |
| CN101830937B (zh) * | 2009-03-12 | 2012-06-06 | 张锦明 | 可视化、双反应管氟-18多功能自动化合成模块 |
| JP2012532164A (ja) * | 2009-07-10 | 2012-12-13 | バイエル ファーマ アクチエンゲゼルシャフト | 放射性トレーサーの精製のための低‐中圧液体クロマトグラフィーの使用 |
| US10639608B2 (en) * | 2010-04-08 | 2020-05-05 | Siemens Medical Solutions Usa, Inc. | System, device and method for preparing tracers and transferring materials during radiosynthesis |
| DE102010036356A1 (de) | 2010-07-12 | 2012-01-12 | Abx Advanced Biochemical Compounds Gmbh | Vorrichtung zur Synthese radioaktiv markierter Verbindungen |
| US20120108858A1 (en) * | 2010-10-28 | 2012-05-03 | Maxim Kiselev | Method and device for manufacturing of radiopharmaceuticals |
| US11504430B2 (en) | 2010-12-29 | 2022-11-22 | Ge Healthcare Limited | Eluent solution |
| US20130060017A1 (en) | 2011-07-15 | 2013-03-07 | Cardinal Health 414, Llc | Methods for synthesizing labeled compounds |
| GB201117785D0 (en) | 2011-10-14 | 2011-11-30 | Ge Healthcare Ltd | Improved radiosynthesis method |
| GB201117786D0 (en) | 2011-10-14 | 2011-11-30 | Ge Healthcare Ltd | Eluent vial |
| GB201120586D0 (en) * | 2011-11-30 | 2012-01-11 | Ge Healthcare Ltd | Solid phase extraction neutralisation |
| US10584078B2 (en) * | 2013-11-13 | 2020-03-10 | Ge Healthcare Limited | Dual run cassette for the synthesis of 18F-labelled compounds |
-
2014
- 2014-11-12 US US15/033,321 patent/US10584078B2/en active Active
- 2014-11-12 HR HRP20250050TT patent/HRP20250050T1/hr unknown
- 2014-11-12 PT PT147967624T patent/PT3068747T/pt unknown
- 2014-11-12 KR KR1020167012207A patent/KR102335535B1/ko active Active
- 2014-11-12 FI FIEP14796762.4T patent/FI3068747T3/fi active
- 2014-11-12 WO PCT/EP2014/074330 patent/WO2015071288A1/en not_active Ceased
- 2014-11-12 CA CA2930479A patent/CA2930479C/en active Active
- 2014-11-12 ES ES14796762T patent/ES3005832T3/es active Active
- 2014-11-12 RS RS20250079A patent/RS66442B1/sr unknown
- 2014-11-12 PL PL14796762.4T patent/PL3068747T3/pl unknown
- 2014-11-12 HU HUE14796762A patent/HUE069777T2/hu unknown
- 2014-11-12 BE BE20145062A patent/BE1022357A9/fr active
- 2014-11-12 JP JP2016528871A patent/JP6496726B2/ja active Active
- 2014-11-12 EP EP14796762.4A patent/EP3068747B1/en active Active
- 2014-11-12 CN CN201410858370.9A patent/CN104762666A/zh active Pending
- 2014-11-12 DK DK14796762.4T patent/DK3068747T3/da active
- 2014-11-12 IL IL23565014A patent/IL235650B/en active IP Right Grant
- 2014-11-12 CN CN202110731994.4A patent/CN113564722A/zh active Pending
- 2014-11-12 DE DE202014010612.6U patent/DE202014010612U1/de not_active Expired - Lifetime
-
2015
- 2015-05-26 DE DE202015007501.0U patent/DE202015007501U1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL235650A0 (en) | 2015-02-26 |
| FI3068747T3 (fi) | 2024-12-30 |
| WO2015071288A1 (en) | 2015-05-21 |
| JP2017503752A (ja) | 2017-02-02 |
| DK3068747T3 (da) | 2025-01-13 |
| DE202015007501U1 (de) | 2015-12-17 |
| EP3068747A1 (en) | 2016-09-21 |
| US20160257622A1 (en) | 2016-09-08 |
| BE1022357B1 (fr) | 2016-03-24 |
| DE202014010612U1 (de) | 2016-04-19 |
| JP6496726B2 (ja) | 2019-04-03 |
| KR102335535B1 (ko) | 2021-12-08 |
| PT3068747T (pt) | 2025-01-24 |
| HRP20250050T1 (hr) | 2025-04-11 |
| CA2930479C (en) | 2023-03-28 |
| EP3068747B1 (en) | 2024-10-30 |
| KR20160085769A (ko) | 2016-07-18 |
| US10584078B2 (en) | 2020-03-10 |
| CN113564722A (zh) | 2021-10-29 |
| CA2930479A1 (en) | 2015-05-21 |
| IL235650B (en) | 2019-10-31 |
| CN104762666A (zh) | 2015-07-08 |
| HUE069777T2 (hu) | 2025-04-28 |
| PL3068747T3 (pl) | 2025-03-10 |
| RS66442B1 (sr) | 2025-02-28 |
| BE1022357A9 (fr) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3005832T3 (en) | Dual run cassette for the synthesis of 18f-labelled compounds | |
| ES2621950T3 (es) | Disolución de eluyente | |
| JP6145107B2 (ja) | 加水分解性脱保護工程及び固相抽出を含む１８ｆ−標識化合物の生産 | |
| KR102109225B1 (ko) | 18f-플루시클로빈의 제조 | |
| ES2953377T3 (es) | Disposición de captación de fluoruro | |
| KR102155932B1 (ko) | Pet 추적자 정제 시스템 | |
| JP7467353B2 (ja) | 固相抽出 |